|Bid||14.90 x 0|
|Ask||14.95 x 0|
|Day's range||14.85 - 14.95|
|52-week range||12.65 - 17.10|
|PE ratio (TTM)||-9.20|
|Earnings date||9 Aug 2017 - 14 Aug 2017|
|Dividend & yield||N/A (N/A)|
|1y target est||12.65|
New Delhi, July 31 (IANS) Acer on Monday launched 'Nitro 5' gaming laptop with Intel's 7th generation Core i7 and i5 processors at Rs 75,990 in India. The laptop is powered by NVIDIA 'GeForce GTX' 1050/1050Ti ...
Acer Therapeutics, a three-year-old Cambridge biotech developing drugs for ultra-rare diseases, said Monday that it will go public through a reverse merger with a small Texas company. Acer said it would merge with Opexa Therapeutics (OPXA), which laid off all but two of its 20 employees after its lead drug for multiple sclerosis flunked a mid-stage trial in October. In connection with the deal, Acer said it would receive a $15.7 million round of financing led by TVM Capital, a life sciences venture firm based in Germany.
After consummation Opexa's name will be changed to Acer Therapeutics Inc.